[go: up one dir, main page]

FR2875404B1 - Composition pharmaceutique pour le traitement de la rosacee - Google Patents

Composition pharmaceutique pour le traitement de la rosacee

Info

Publication number
FR2875404B1
FR2875404B1 FR0409879A FR0409879A FR2875404B1 FR 2875404 B1 FR2875404 B1 FR 2875404B1 FR 0409879 A FR0409879 A FR 0409879A FR 0409879 A FR0409879 A FR 0409879A FR 2875404 B1 FR2875404 B1 FR 2875404B1
Authority
FR
France
Prior art keywords
rosacea
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0409879A
Other languages
English (en)
Other versions
FR2875404A1 (fr
Inventor
William Robert Pilgrim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0409879A priority Critical patent/FR2875404B1/fr
Priority to EP05802503A priority patent/EP1791598A1/fr
Priority to PCT/FR2005/002281 priority patent/WO2006032759A1/fr
Priority to CA002578121A priority patent/CA2578121A1/fr
Priority to JP2007531796A priority patent/JP2008513420A/ja
Publication of FR2875404A1 publication Critical patent/FR2875404A1/fr
Priority to US11/723,378 priority patent/US20070219263A1/en
Application granted granted Critical
Publication of FR2875404B1 publication Critical patent/FR2875404B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0409879A 2004-09-17 2004-09-17 Composition pharmaceutique pour le traitement de la rosacee Expired - Fee Related FR2875404B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0409879A FR2875404B1 (fr) 2004-09-17 2004-09-17 Composition pharmaceutique pour le traitement de la rosacee
EP05802503A EP1791598A1 (fr) 2004-09-17 2005-09-14 Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee
PCT/FR2005/002281 WO2006032759A1 (fr) 2004-09-17 2005-09-14 Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee
CA002578121A CA2578121A1 (fr) 2004-09-17 2005-09-14 Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee
JP2007531796A JP2008513420A (ja) 2004-09-17 2005-09-14 アゼライン酸と組合せたメトロニダゾールのしゅさの処置のための使用
US11/723,378 US20070219263A1 (en) 2004-09-17 2007-03-19 Metronidazole/azelaic acid compositions for the treatment of rosacea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0409879A FR2875404B1 (fr) 2004-09-17 2004-09-17 Composition pharmaceutique pour le traitement de la rosacee

Publications (2)

Publication Number Publication Date
FR2875404A1 FR2875404A1 (fr) 2006-03-24
FR2875404B1 true FR2875404B1 (fr) 2008-10-03

Family

ID=34951421

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0409879A Expired - Fee Related FR2875404B1 (fr) 2004-09-17 2004-09-17 Composition pharmaceutique pour le traitement de la rosacee

Country Status (6)

Country Link
US (1) US20070219263A1 (fr)
EP (1) EP1791598A1 (fr)
JP (1) JP2008513420A (fr)
CA (1) CA2578121A1 (fr)
FR (1) FR2875404B1 (fr)
WO (1) WO2006032759A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316308B1 (es) * 2008-04-30 2010-02-15 Fundacion Universitaria San Pablo - Ceu Medicamento a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion.
CA3158316A1 (fr) * 2019-10-16 2021-04-22 Curology, Inc. Compositions et methodes de traitement de l'acne et du photovieillissement
RU2741988C1 (ru) * 2020-08-05 2021-02-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ коррекции антиоксидантного статуса при лечении больных эритематозно-телеангиэктатической и папуло-пустулезной формами розацеа легкой и средней степени тяжести
CN120309545A (zh) * 2024-01-15 2025-07-15 中国药科大学 一种甲硝唑衍生物、制备方法及在药物制备中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1393221A (zh) * 2001-06-22 2003-01-29 姜涛 一种治疗痤疮的药液
US7060729B2 (en) * 2002-09-05 2006-06-13 Reza Babapour Composition and method for treating skin
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient
JP2006527219A (ja) * 2003-06-10 2006-11-30 シエーリング アクチエンゲゼルシャフト アルカンジカルボン酸および薬学的に活性な成分から成る組成物

Also Published As

Publication number Publication date
WO2006032759A1 (fr) 2006-03-30
US20070219263A1 (en) 2007-09-20
EP1791598A1 (fr) 2007-06-06
FR2875404A1 (fr) 2006-03-24
CA2578121A1 (fr) 2006-03-30
JP2008513420A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
EP2322221A4 (fr) Composition pharmaceutique pour le traitement et la prévention du cancer
EP1848431A4 (fr) Formulations liquides pour le traitement de maladies ou affections
EP2154971A4 (fr) Combinaison pharmaceutique synergique pour le traitement du cancer
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP1985302A4 (fr) Médicament pour le traitement de tumeurs et son utilisation
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
EP1755584A4 (fr) Traitement de la myopie
EP1765288A4 (fr) Methodes de traitement d'infections endobronchiques
EP2376091A4 (fr) Nouvelles cibles pour le traitement de l'hypercholestérolémie
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
EP1804787A4 (fr) Composition flavonoide pour le traitement des maladies bucco-dentaires
EP2296665A4 (fr) Composition pharmaceutique destinée au traitement de l'éjaculation précoce
EP2305300A4 (fr) Composition pharmaceutique destinée au traitement et à la prévention du cancer
EP1773970A4 (fr) Formules de lubrifiants pour le traitement de toles
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
EP2231146A4 (fr) Composition pharmaceutique pour le traitement et la prévention du glaucome
EP2015741A4 (fr) Inhibiteurs de l'histone desacétylase pour le traitement de la neurodégénération
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
EP1889618A4 (fr) Médicament combiné pour le traitement du diabète
FR2875404B1 (fr) Composition pharmaceutique pour le traitement de la rosacee
DE602005007485D1 (de) Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose
EP2222295A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention de maladies rénales

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20100531